Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
“We are delighted to partner with Sato, who share our mission to provide meaningful innovation to individuals suffering from immune-mediated skin diseases.
- “We are delighted to partner with Sato, who share our mission to provide meaningful innovation to individuals suffering from immune-mediated skin diseases.
- Topical roflumilast has been shown to effectively clear skin and reduce itch, with a safe and well-tolerated profile.
- With this collaboration, we believe we can make an impact for individuals suffering from immune-mediated skin diseases in Japan,” said Seiichi Sato, president and chief executive officer, Sato.
- Sato will be responsible for development, manufacturing, and commercialization of roflumilast cream and roflumilast foam and other topical roflumilast presentations in Japan.